Groundbreaking emergency
treatment for vasospasm & stroke.

Two-minute non-invasive
neuro stimulation treatment.

Patents issued in China, Europe,
and the United States.

CEREFAST controls cerebral vasodilation
and cerebral diffusion.

CAUTION – Investigational device. Not yet approved by US FDA for sale. Limited by United States law to investigational use.

Click on the video for a 2-minute overview of VACERE’s product and technology

A Groundbreaking
Emergency Treatment
for Stroke & Vasospasm

  • Easy, non-invasive, neuro stimulation treatment.
  • Relaxes cerebral arteries, allowing superior blood perfusion.
  • Just one, 2-minute stimulation.

Our Leadership Team

Jeffrey Lietzke

Jeffrey Lietzke

CEO

20 years of medtech founding, commercialization, and exit experience.

Emilio Sacristan, PhD

Emilio Sacristan, PhD

PhD Chief Science Officer, Co-Founder and Director

Co-inventor of the CEREFAST.

Stephanie Harrington, MS

Stephanie Harrington, MS

Chief Clinical and Regulatory Officer

20 years of experience in the medical device industry.

Guy Jean L. Savoir

Guy Jean L. Savoir

Director

Businessman, entrepreneur and investor in the pharmaceutical and health-care industries.

Dr. John Andrefsky

Dr. John Andrefsky

Clinical Advisory Board

Vascular Neurologist at University Hospitals. Fellowship-trained in neurocritical care, Cleveland Clinic. 

Pre-clinical &
Clinical Testing

  • Completed healthy human subjects trial establishing safety, tolerability, and dose response.
  • Clinical data in cerebral vasospasm patients showed a reduction of death-and-disability rates from 50% to 0% in a six-subject study when used to reverse vasospasm in the Neuro-ICU.
  • 10 peer-reviewed scientific papers published to date.

Increase in brain perfusion index after one stimulation in blue; and after two stimulations 120 minutes apart in red.

Approach to Market

 

Market Neurosurgery ICUs Emergency Departments Ambulances
Indication Vasospasm Ischemic Stroke Ischemic Stroke
Regulatory ~ 12 months from
FDA market clearance
Expedited Access PMA
( Class IIa in E.U.)
Expedited Access PMA
( Class IIa in E.U.)

 

Groundbreaking emergency
treatment for vasospasm & stroke.

Two-minute non-invasive
magnetic stimulation treatment.

US FDA Humanitarian Use Designation
confirmed for vasospasm.

Testing device eggectiveness
against migraines.

CAUTION – Investigational device. Not yet approved by US FDA for sale. Limited by United States law to investigational use.

Click on the video for a 2-minute overview of VACERE’s product and technology

A groundbreaking emergency treatment for stroke & vasospasm

  • Easy, non-invasive, neuro stimulation treatment.
  • Relaxes cerebral arteries, allowing superior blood perfusion.
  • Just one, 2-minute stimulation.

Our Leadership Team

Jeffrey Lietzke

Jeffrey Lietzke

CEO

20 years of medtech founding, commercialization, and exit experience.

Emilio Sacristan, PhD

Emilio Sacristan, PhD

PhD Chief Science Officer, Co-Founder and Director

Co-inventor of the CEREFAST.

Stephanie Harrington, MS

Stephanie Harrington, MS

Chief Clinical and Regulatory Officer

20 years of experience in the medical device industry.

Guy Jean L. Savoir

Guy Jean L. Savoir

Director

Businessman, entrepreneur and investor in the pharmaceutical and health-care industries.

Dr. John Andrefsky

Dr. John Andrefsky

Clinical Advisory Board

Vascular Neurologist at University Hospitals. Fellowship-trained in neurocritical care, Cleveland Clinic.

Pre-clinical & Clinical Testing

  • Completed healthy human subjects trial establishing safety, tolerability, and dose response.
  • Clinical data in cerebral vasospasm patients showed a reduction of death-and-disability rates from 50% to 0% in a six-subject study when used to reverse vasospasm in the Neuro-ICU.
  • 10 peer-reviewed scientific papers published to date.

Increase in brain perfusion index after one stimulation in blue; and after two stimulations 120 minutes apart in red.

Approach to Market

 

Market Neurosurgery ICUs Emergency Departments Ambulances
Indication Vasospasm Ischemic Stroke Ischemic Stroke
Regulatory ~ 12 months from
FDA market clearance
Expedited Access PMA
( Class IIa in E.U.)
Expedited Access PMA
( Class IIa in E.U.)

 

Groundbreaking emergency
treatment for vasospasm & stroke.

Two-minute non-invasive
neuro stimulation treatment.

Patents issued in China, Europe,
and the United States.

CEREFAST controls cerebral vasodilation
and cerebral diffusion.

CAUTION – Investigational device. Not yet approved by US FDA for sale. Limited by United States law to investigational use.

Click on the video for a 2-minute overview of VACERE’s product and technology

A groundbreaking emergency treatment for stroke & vasospasm

  • Easy, non-invasive, magnetic stimulation treatment
  • Relaxes cerebral arteries, allowing superior blood perfusion
  • Just one, 2-minute stimulation

Our Leadership Team

Jeffrey Lietzke

Jeffrey Lietzke

CEO

20 years of medtech founding, commercialization, and exit experience.

Emilio Sacristan, PhD

Emilio Sacristan, PhD

PhD Chief Science Officer, Co-Founder and Director

Co-inventor of the CEREFAST.

Stephanie Harrington, MS

Stephanie Harrington, MS

Chief Clinical and Regulatory Officer

20 years of experience in the medical device industry.

Guy Jean L. Savoir

Guy Jean L. Savoir

Director

Businessman, entrepreneur and investor in the pharmaceutical and health-care industries.

Dr. John Andrefsky

Dr. John Andrefsky

Clinical Advisory Board

Vascular Neurologist at University Hospitals. Fellowship-trained in neurocritical care, Clevland Clinic.

Pre-clinical & Clinical Testing

  • Completed healthy human subjects trial establishing safety, tolerability, and dose response.
  • Clinical data in cerebral vasospasm patients showed a reduction of death-and-disability rates from 50% to 0% in a six-subject study when used to reverse vasospasm in the Neuro-ICU.
  • 10 peer-reviewed scientific papers published to date.

Increase in brain perfusion index after one stimulation in blue; and after two stimulations 120 minutes apart in red.

Approach to Market

 

Market
Neurosurgery ICUs
Indication
Vasospasm
Regulatory
~ 12 months from
FDA market clearance

 

Market
Emergency Departments
Indication
Ischemic Stroke
Regulatory
Expedited Access PMA

( Class IIa in E.U.)

 

Market
Ambulances
Indication
Ischemic Stroke
Regulatory
Expedited Access PMA

( Class IIa in E.U.)

 

Learn More and Contact Us

2 + 13 =

You can also email us direct at: Inquiries@vacere.com